Global Oral Solid Dosage Contract Manufacturing Industry Market Research 2030

  • Product Code:
  • Published Date:
    11 Oct 2021
  • Region:
  • Pages:
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:

Impact Analysis on the Growth of Market

Inflation and Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.



The Research Report is Updated with 2021 Base Year, 2022 Estimated year and Forecast till 2031 with Market Insights.

With the dip in global production, the GDP has contracted in 2020 and impacted the market across the world. Upon placing a Sample Request, you will receive an updated report with 2021 as base year, 2022 as estimated year and forecast to 2031. This will have market drivers, recovery rate in the market, insights and competitive analysis.

Market Overview:

Translate Report

"Large pharmaceutical companies are facing increased research costs for new chemical entities. In order to reduce these costs, the company is now focusing on outsourcing primary (API) and secondary (recipe) manufacturing. Outsourcing secondary manufacturing of branded products can save innovative companies about 40% to 60% of their costs. In addition to cost savings, innovative companies also seek to expand operations, flexibility and diversity.
Due to continuous efforts to reduce costs, the demand for oral solid dose contract manufacturing has increased significantly. On the other hand, CMOs are paying more and more attention to integrating into the value chain of pharmaceutical companies, which has also accelerated the demand for contract manufacturing of oral solid dosage forms. CMOs are building dedicated facilities or capabilities for pharmaceutical companies, and pharmaceutical companies are reluctant to build them themselves. For example, in October 2020, Lonza announced an investment of US$93 million in its capsule and healthy ingredients division (CHI). 

The CHI division is a supply partner of dosage forms for the nutrition and biopharmaceutical industries. This investment is to help the company increase the overall capsule production capacity of CHI's Capsugel product portfolio. In its new research, Persistence Market Research, a market research and consulting company, has gained insight into the key drivers of the demand for oral solid dose contract manufacturing. The report tracks the global trend of oral solid dose contract manufacturing in more than 20 high-growth markets, and analyzes the impact of COVID-19 on the entire healthcare industry, especially the impact on oral solid dose contract manufacturing.


 History and future market outlook : 

CMOs previous business model was based on sales and production. However, the current CMO industry is undergoing major changes in business models, reflecting the dynamics of the pharmaceutical industry. For example, large pharmaceutical companies emphasize cost reduction and better differentiate with their peers to reduce price competition. Its strategies are based on the conditions and assumptions of the pharmaceutical industry, such as the expected increase in unit sales and the increase in reserved drug prices; pharmaceutical companies have stopped investing in internal capacity and are accepting outsourcing. In addition, the single manufacturing activity in the past is being transformed into one-stop service or into CDMO, which is beneficial to both pharmaceutical and CDMO customers. These companies are helping to move products from clinical to commercial locations quickly and profitably. Therefore, these drastic changes in the business model adopted by the CMO or CDMO are expected to bring prospects for the contract manufacturing of oral solid doses. Customize this report


According to Kenneth Market Research analysis: 

The oral solid dose contract manufacturing market expanded at a compound annual growth rate of 6% between 2022 and 2030, which will have a significant adverse impact on the biopharmaceutical industry and the entire healthcare industry. The COVID-19 crisis has caused several short-term and long-term effects. The decline in sales can be attributed to labor shortages and manufacturers; increasing focus on investing in COVID-19 product development. 

In addition, the disruption of the raw material supply chain and the economic impact of the pandemic on SMEs are also factors that have a negative impact on the market. However, with the emergence of vaccines and positive changes in the open economy, the oral solid dose contract manufacturing market is expected to achieve substantial growth during the forecast period. 


 Will the growing demand for new therapies drive the manufacture of solid medicines?

 The increase in life-threatening viruses and chronic diseases around the world has led to an increase in the demand for new therapies to prevent and cure the affected population. Medicinal products are preventive or therapeutic drugs derived from metabolites naturally present in organisms. 


The increase in drug consumption among patients with various diseases has created a high demand for the large-scale manufacturing of new therapeutic drugs. Therefore, the increased demand for large-scale manufacturing has led to an increase in contract manufacturing outsourcing by major pharmaceutical companies. Therefore, it can be concluded that the increasing demand for new therapies will drive the demand for contract manufacturing of oral solid doses. In addition, economic prosperity and increased health awareness are also expected to promote market expansion in the next few years.


 How will the installation of new pharmaceutical contract manufacturing facilities affect the market? 
The huge growth of pharmaceutical contract manufacturing companies is mainly due to the increased demand for pharmaceutical manufacturing by pharmaceutical companies through outsourcing. Over the years, solid pharmaceutical manufacturing has increased globally, thereby driving the demand for pharmaceutical contract manufacturing services.


 As demand increases, contract manufacturing companies are increasingly concerned about expansion. Companies, especially those in the Asia-Pacific region such as China, India and Japan, are investing heavily in the establishment of new contract manufacturing centers. In order to emphasize the speed of pharmaceutical contract manufacturing to meet global demand as well as the availability of labor and lower production costs, major companies are more willing to establish new manufacturing plants in the region. For example, in July 2020, CMIC HOLDINGS Co., Ltd. set up a new contract manufacturing plant in CMIC BIO Co., Ltd. in Japan to provide contract manufacturing and development services for participants in the pharmaceutical market outside Asia, Europe and other Asian countries. And the United States.


 Competitive landscape: 

Major players in the oral solid-dose contract manufacturing field focus on geographic expansion to increase revenue, and they have added new maintenance and service centers in emerging countries through the acquisition of local players. For example, in December 2020, the leading contract development and manufacturing organization (CDMO) Piramal Enterprises Ltd Pharmaceutical Solutions Business announced plans to expand its Michigan plant to add new capabilities and active pharmaceutical ingredient (API) development and manufacturing capabilities. 
The company aims to expand its manufacturing facilities by creating a new contract manufacturing center. On the other hand, few participants focus on modifying and developing a strong service portfolio through strategic business partnerships with pharmaceutical organizations.


For example, in June 2020, CMIC HOLDINGS Co., Ltd. announced the signing of a cooperation agreement with Yamanashi Prefecture. Some leading companies operating in the market are: Abbvie Inc. ThermoFisher Scientific Inc. (Patheon NV) Pfizer Inc. Lonza Group AG Catalent Inc. Jubilant Pharmova Piramal Enterprises Ltd. Wockhardt Ltd. CMIC HOLDINGS Co., LTD Mayne Pharma (Metric Contract Services) A​​lcami Corporation Cambrex Corporation (Halo Pharma) CordenPharma International GEVION CorporationArnet PharmaceuticalsPharma Tech Industries Tower Laboratories Ltd.PNP Pharmaceuticals Inc.Confab Laboratories Inc.

Main market segments:

 Product Tablets OTC Capsule OTC Powders and Granules (MT) OTC Release Mechanism Tablets Immediate Release Modifications Controlled Release Enteric Coated Other Chewable Tablets Drugs Effervescent Tablets and User Controlled Release Companies Virtual Pharmaceuticals Small or large doses or biotech pharmaceutical companies"

Geography Analysis:

The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

  • North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys  & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
  • Middle East and Africa  (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook


Please enter your personal details below
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
Please enter your personal details below
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports